Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature.
Courtney B CrayneEsraa EloseilyMelissa L MannionSaji P AzerfPeter WeiserTimothy BeukelmanMatthew L StollDaniel I FeigT Prescott AtkinsonRandy Quentin CronPublished in: Pediatric rheumatology online journal (2018)
Overall, RTX effectively reduced the number of hospital admissions and oral CS burden. RTX also helped most all children achieve clinical remission. RTX appears to be an effective and safe alternative for chronic CS dependent and immunomodulatory refractory childhood HSP.